New Ray Medicine International Holding Limited (6108:HK) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the New Ray Medicine International Holding Limited stock forecast from 0 analysts, the average analyst target price for New Ray Medicine International Holding Limited is not available over the next 12 months. New Ray Medicine International Holding Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of New Ray Medicine International Holding Limited is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, New Ray Medicine International Holding Limited’s stock price was HKD 0.054. New Ray Medicine International Holding Limited’s stock price has changed by -8.47% over the past week, +38.46% over the past month and +10.20% over the last year.
No recent analyst target price found for New Ray Medicine International Holding Limited
No recent average analyst rating found for New Ray Medicine International Holding Limited
Company Overview New Ray Medicine International Holding Limited
New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of injection drugs and pharmaceutical products in the People's Republic of China. The company's pharmaceutical products include injections, capsules, tablets, and other drugs for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, parenteral nutrition, hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B and chronic hepatitis C, respiratory tract infections, urinary tract infections, genitourinary system infections, intra-abdominal infections, bone and joint infections, septicemia, catabolism, hypermetabolism, pneumonia, skin and soft tissue infections, pelvic inflammatory, diarrhea and digestive system relevant illness, biliary tract infection, and other infections. It also offers marketing and promotion services of drugs. The company was founded in 2001 and is headquartered in Hangzhou, the People's Republic of China. Read Less
New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of injection drugs and pharmaceutical products in the People's Republic of China. The company's pharmaceutical products include injections, capsules, tablets, and ot...Read More
Frequently Asked Questions About New Ray Medicine International Holding Limited (6108:HK) Stock
Stock Target Advisor's fundamental analysis for New Ray Medicine International Holding Limited's stock is Bearish.
Unfortunately we do not have enough data on 6108:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6108:HK's stock to indicate what its average analyst target is.
6108:HK stock's Price/Earning ratio is 0.07.
Our analysis grades 6108:HK stock's Price / Earning ratio at A+. This means that 6108:HK stock's Price/Earning ratio is above 0% of the stocks in the Pharmaceutical Retailers sector in the HK exchange.
Based on this 6108:HK may be undervalued for its sector.
The last closing price of 6108:HK's stock was HKD 0.05.
The most recent market capitalization for 6108:HK is HKD 0.09B.
Unfortunately we do not have enough analyst data on 6108:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains New Ray Medicine International Holding Limited's stock.
As per our most recent records New Ray Medicine International Holding Limited has 23 Employees.
New Ray Medicine International Holding Limited's registered address is Dikai International Center, Hangzhou, China.
You can get more information about it from New Ray Medicine International Holding Limited's website at https://www.newraymedicine.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About New Ray Medicine International Holding Limited (6108:HK) Stock
Stock Target Advisor's fundamental analysis for New Ray Medicine International Holding Limited's stock is Bearish.
Unfortunately we do not have enough data on 6108:HK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6108:HK's stock to indicate what its average analyst target is.
6108:HK stock's Price/Earning ratio is 0.07.
Our analysis grades 6108:HK stock's Price / Earning ratio at A+. This means that 6108:HK stock's Price/Earning ratio is above 0% of the stocks in the Pharmaceutical Retailers sector in the HK exchange.
Based on this 6108:HK may be undervalued for its sector.
The last closing price of 6108:HK's stock was HKD 0.05.
The most recent market capitalization for 6108:HK is HKD 0.09B.
Unfortunately we do not have enough analyst data on 6108:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains New Ray Medicine International Holding Limited's stock.
As per our most recent records New Ray Medicine International Holding Limited has 23 Employees.
New Ray Medicine International Holding Limited's registered address is Dikai International Center, Hangzhou, China.
You can get more information about it from New Ray Medicine International Holding Limited's website at https://www.newraymedicine.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6108:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
